Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
1 finding from 1 review
Change in neurocognitive function · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
1 finding from 1 review
Quality of life · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Corticosteroid requirements · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in oedema (T2 hyperintensity) · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
Edaravone plus corticosteroids showed no clear difference in reduction in oedema (T2 hyperintensity) compared with corticosteroids (low certainty).
1 finding from 1 review
Reduction in post‐gadolinium enhancement · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
Edaravone plus corticosteroids showed no clear difference in reduction in post‐gadolinium enhancement compared with corticosteroids (low certainty).
1 finding from 1 review
Improvement in LENT/SOMA · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
Edaravone plus corticosteroids may leads to higher improvement in LENT/SOMA compared with corticosteroids (low certainty).
1 finding from 1 review
Complete resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher complete resolution of phimosis compared with placebo or no treatment (low certainty).
2 findings from 1 review
Partial resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher partial resolution of phimosis compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in retractability score · boys up to 18 years old with phimosis
It is very uncertain whether topical corticosteroids changes change in retractability score compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse effects (any) · boys up to 18 years old with phimosis
Topical corticosteroids showed no clear difference in adverse effects (any) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Need for nasal continuous positive airway pressure · patients with the management of transient tachypnea of the newborn
It is very uncertain whether inhaled corticosteroids changes need for nasal continuous positive airway pressure compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether inhaled corticosteroids changes need for mechanical ventilation compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Length of hospital stay · patients with the management of transient tachypnea of the newborn
1 finding from 1 review